Which has stronger valuation and earnings, ELVN or CLYM?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is ELVN or CLYM more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Climb Bio N/A -31.45% -30.39%

Does the media prefer ELVN or CLYM?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Climb Bio. MarketBeat recorded 4 mentions for Enliven Therapeutics and 2 mentions for Climb Bio. Enliven Therapeutics' average media sentiment score of 0.91 beat Climb Bio's score of 0.37 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, VERA or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is VERA or CLYM more profitable?

Climb Bio's return on equity of -31.45% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -74.86% -60.18% Climb Bio N/A -31.45% -30.39%

Does the media favor VERA or CLYM?

In the previous week, Vera Therapeutics and Vera Therapeutics both had 2 articles in the media. Vera Therapeutics' average media sentiment score of 0.92 beat Climb Bio's score of 0.37 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, CLYM or IRON?

Climb Bio is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is CLYM or IRON more profitable?

Climb Bio's return on equity of -31.45% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Disc Medicine N/A -36.94% -33.88%

Does the media prefer CLYM or IRON?

In the previous week, Disc Medicine had 4 more articles in the media than Climb Bio. MarketBeat recorded 6 mentions for Disc Medicine and 2 mentions for Climb Bio. Disc Medicine's average media sentiment score of 0.51 beat Climb Bio's score of 0.37 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RGC or CLYM?

Climb Bio has a consensus price target of $21.73, suggesting a potential upside of 71.08%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Climb Bio 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07

Which has better earnings & valuation, RGC or CLYM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is RGC or CLYM more profitable?

Regencell Bioscience's return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Climb Bio N/A -31.45% -30.39%

Does the media favor RGC or CLYM?

In the previous week, Climb Bio had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Regencell Bioscience. Climb Bio's average media sentiment score of 0.37 beat Regencell Bioscience's score of -0.35 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, MBX or CLYM?

MBX Biosciences is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is MBX or CLYM more profitable?

MBX Biosciences' return on equity of -24.52% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Climb Bio N/A -31.45% -30.39%

Does the media refer more to MBX or CLYM?

In the previous week, MBX Biosciences had 8 more articles in the media than Climb Bio. MarketBeat recorded 10 mentions for MBX Biosciences and 2 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.37 beat MBX Biosciences' score of 0.36 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Climb Bio (CLYM) Competitors

$12.70 +0.12 (+0.95%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$12.68 -0.01 (-0.12%)

As of 07/17/2026 07:03 PM Eastern

Compare

CLYM vs. ELVN, VERA, IRON, RGC, and MBX

Should you buy Climb Bio stock or one of its competitors? MarketBeat compares Climb Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Climb Bio include Enliven Therapeutics (ELVN), Vera Therapeutics (VERA), Disc Medicine (IRON), Regencell Bioscience (RGC), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.

How does Climb Bio compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Enliven Therapeutics had 2 more articles in the media than Climb Bio. MarketBeat recorded 4 mentions for Enliven Therapeutics and 2 mentions for Climb Bio. Enliven Therapeutics' average media sentiment score of 0.91 beat Climb Bio's score of 0.37 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics currently has a consensus target price of $69.17, suggesting a potential upside of 30.01%. Climb Bio has a consensus target price of $21.73, suggesting a potential upside of 71.08%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Enliven Therapeutics' return on equity of -21.04% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Climb Bio	N/A	-31.45%	-30.39%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Enliven Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

Summary

Enliven Therapeutics and Climb Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Climb Bio compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Climb Bio's return on equity of -31.45% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Climb Bio	N/A	-31.45%	-30.39%

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vera Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

Vera Therapeutics currently has a consensus price target of $84.58, suggesting a potential upside of 119.70%. Climb Bio has a consensus price target of $21.73, suggesting a potential upside of 71.08%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Climb Bio is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

In the previous week, Vera Therapeutics and Vera Therapeutics both had 2 articles in the media. Vera Therapeutics' average media sentiment score of 0.92 beat Climb Bio's score of 0.37 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vera Therapeutics beats Climb Bio on 7 of the 13 factors compared between the two stocks.

How does Climb Bio compare to Disc Medicine?

Climb Bio (NASDAQ:CLYM) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Climb Bio is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

In the previous week, Disc Medicine had 4 more articles in the media than Climb Bio. MarketBeat recorded 6 mentions for Disc Medicine and 2 mentions for Climb Bio. Disc Medicine's average media sentiment score of 0.51 beat Climb Bio's score of 0.37 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Climb Bio's return on equity of -31.45% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Disc Medicine	N/A	-36.94%	-33.88%

Climb Bio currently has a consensus target price of $21.73, indicating a potential upside of 71.08%. Disc Medicine has a consensus target price of $104.44, indicating a potential upside of 37.16%. Given Climb Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Climb Bio is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Climb Bio beats Disc Medicine on 8 of the 14 factors compared between the two stocks.

How does Climb Bio compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Climb Bio (NASDAQ:CLYM) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

In the previous week, Climb Bio had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Regencell Bioscience. Climb Bio's average media sentiment score of 0.37 beat Regencell Bioscience's score of -0.35 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Climb Bio has a consensus price target of $21.73, suggesting a potential upside of 71.08%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Regencell Bioscience's return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Climb Bio	N/A	-31.45%	-30.39%

Regencell Bioscience has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Climb Bio beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks.

How does Climb Bio compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Climb Bio (NASDAQ:CLYM) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

MBX Biosciences has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market.

69.8% of Climb Bio shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MBX Biosciences is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

MBX Biosciences presently has a consensus price target of $63.00, indicating a potential upside of 0.13%. Climb Bio has a consensus price target of $21.73, indicating a potential upside of 71.08%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

In the previous week, MBX Biosciences had 8 more articles in the media than Climb Bio. MarketBeat recorded 10 mentions for MBX Biosciences and 2 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.37 beat MBX Biosciences' score of 0.36 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences' return on equity of -24.52% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Climb Bio	N/A	-31.45%	-30.39%

Summary

Climb Bio beats MBX Biosciences on 9 of the 14 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLYM vs. The Competition

Export

Metric	Climb Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$727.24M	$3.69B	$6.86B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-16.28	21.03	27.25	23.92
Price / Sales	N/A	177.66	517.83	88.82
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	3.78	8.26	10.69	6.18
Net Income	-$59.85M	$23.83M	$3.59B	$332.29M
7 Day Performance	-9.29%	-3.47%	-2.20%	-2.05%
1 Month Performance	10.92%	2.69%	1.63%	-2.18%
1 Year Performance	741.06%	45.93%	25.64%	17.67%

Climb Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLYM Climb Bio	2.978 of 5 stars	$12.70 +1.0%	$21.73 +71.1%	+741.1%	$727.24M	N/A	N/A	9	News Coverage Gap Down
ELVN Enliven Therapeutics	3.2107 of 5 stars	$51.09 -2.1%	$69.17 +35.4%	+134.8%	$3.11B	N/A	N/A	50	Gap Down
VERA Vera Therapeutics	3.5894 of 5 stars	$42.00 -1.1%	$84.58 +101.4%	+67.0%	$3.01B	N/A	N/A	40	Gap Down High Trading Volume
IRON Disc Medicine	2.3507 of 5 stars	$76.59 -3.0%	$104.44 +36.4%	+31.8%	$2.92B	N/A	N/A	30	Insider Trade
RGC Regencell Bioscience	0.2423 of 5 stars	$5.88 -3.1%	N/A	-65.4%	$2.91B	N/A	N/A	10	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLYM) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Competitors

CLYM vs. ELVN, VERA, IRON, RGC, and MBX

How does Climb Bio compare to Enliven Therapeutics?

Summary

How does Climb Bio compare to Vera Therapeutics?

Summary

How does Climb Bio compare to Disc Medicine?

Summary

How does Climb Bio compare to Regencell Bioscience?

Summary

How does Climb Bio compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Climb Bio (CLYM) Competitors

CLYM vs. ELVN, VERA, IRON, RGC, and MBX

How does Climb Bio compare to Enliven Therapeutics?

Do institutionals and insiders hold more shares of ELVN or CLYM?

Does the media prefer ELVN or CLYM?

Do analysts rate ELVN or CLYM?

Is ELVN or CLYM more profitable?

Which has stronger valuation and earnings, ELVN or CLYM?

Which has more volatility & risk, ELVN or CLYM?

Summary

How does Climb Bio compare to Vera Therapeutics?

Is VERA or CLYM more profitable?

Do institutionals & insiders hold more shares of VERA or CLYM?

Which has more volatility and risk, VERA or CLYM?

Do analysts rate VERA or CLYM?

Which has preferable earnings & valuation, VERA or CLYM?

Does the media favor VERA or CLYM?

Summary

How does Climb Bio compare to Disc Medicine?

Do institutionals and insiders have more ownership in CLYM or IRON?

Which has preferable earnings & valuation, CLYM or IRON?

Does the media prefer CLYM or IRON?

Which has more volatility & risk, CLYM or IRON?

Is CLYM or IRON more profitable?

Do analysts rate CLYM or IRON?

Summary

How does Climb Bio compare to Regencell Bioscience?

Which has better earnings & valuation, RGC or CLYM?

Does the media favor RGC or CLYM?

Do analysts prefer RGC or CLYM?

Is RGC or CLYM more profitable?

Which has more risk & volatility, RGC or CLYM?

Do insiders and institutionals have more ownership in RGC or CLYM?

Summary

How does Climb Bio compare to MBX Biosciences?

Which has more risk & volatility, MBX or CLYM?

Do institutionals and insiders believe in MBX or CLYM?

Which has preferable earnings and valuation, MBX or CLYM?

Do analysts recommend MBX or CLYM?

Does the media refer more to MBX or CLYM?

Is MBX or CLYM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools